Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
SVR12, %<br />
S<strong>of</strong>osbuvir-Ledipasvir<br />
N=355<br />
Treatment naïve,<br />
n=170<br />
Week 0 8 1<br />
2<br />
LDV/SOF<br />
LDV/SOF<br />
LDV/SOF + RBV<br />
LDV/SOF + RBV<br />
20<br />
SVR12<br />
24<br />
LDV/SOF 8 wk LDV/SOF + RBV 8 wk<br />
LDV/SOF 12 wk LDV/SOF + RBV 12 wk<br />
95 90 98 98 94 100 100<br />
IFN experienced,<br />
n=74<br />
LDV/SOF<br />
LDV/SOF + RBV<br />
SOF experienced,<br />
n=11<br />
LDV/SOF + RBV<br />
• Randomized, open-label study at 4 sites in Egypt<br />
• Treatment naïve and IFN experienced patients<br />
• Randomized to treatment, stratified by presence/absence <strong>of</strong><br />
cirrhosis<br />
• Approximately 25% with compensated cirrhosis<br />
• SOF experienced patients<br />
• prior treatment with SOF + RBV for 12 or 24 weeks or LDV/SOF ±<br />
RBV for 8 weeks<br />
• assigned to LDV + SOF + RBV for 12 weeks<br />
Shiha G. et al., AASLD 2016<br />
41<br />
43<br />
38<br />
42<br />
42<br />
43<br />
Treatment Naïve<br />
41<br />
42<br />
34<br />
36<br />
38<br />
38<br />
IFN<br />
Experienced<br />
11<br />
11<br />
SOF<br />
Experienced<br />
6
Change language